Wuxi Zhikang Hongyi Biotechnology

Zhikang Hongyi is a clinical-stage biopharmaceutical company headquartered in Wuxi, China, dedicated to the discovery and development of innovative biologics for oncology, autoimmune, and metabolic diseases. The company maintains a diverse pipeline featuring next-generation modalities such as bispecific antibodies and antibody-drug conjugates (ADCs) targeting high-value pathways including Claudin 18.2, CD47/PD-L1, and EGFR/c-Met. Zhikang Hongyi operates a fully integrated R&D ecosystem that encompasses early-stage discovery, CMC, and global clinical development. With multiple programs in Phase 1 and Phase 2 trials across China and the U.S., the company aims to address significant unmet medical needs through precision medicine and differentiated therapeutic strategies.